High Growth Tech Stocks To Watch In February 2025

Over the last 7 days, the United States market has dropped 3.9%, yet it remains up by 17% over the past year with earnings projected to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue and earnings growth despite short-term market fluctuations.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	29.79%	27.57%	★★★★★★
Travere Therapeutics	28.44%	65.05%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
AVITA Medical	27.78%	55.33%	★★★★★★
TG Therapeutics	29.48%	45.20%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	22.67%	58.73%	★★★★★★
Alvotech	31.17%	100.18%	★★★★★★
Blueprint Medicines	22.38%	55.75%	★★★★★★
Lumentum Holdings	21.24%	119.37%	★★★★★★

Click here to see the full list of 225 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

VNET Group (NasdaqGS:VNET)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: VNET Group, Inc. is an investment holding company that offers hosting and related services in China with a market capitalization of approximately $3.55 billion.

Operations: VNET Group generates revenue primarily from hosting and related services, amounting to CN¥7.91 billion. The company's business model focuses on providing these services within China.

VNET Group's strategic alliance with Dajia Investment Holding to invest in hyperscale data centers underscores its commitment to expanding its footprint in China's burgeoning infrastructure sector. With an anticipated annual revenue growth of 11.7%, VNET is outpacing the U.S. market average of 8.8%. Despite current unprofitability and a volatile share price, the company is expected to see earnings skyrocket by 77.7% annually over the next three years, signaling a robust potential turnaround fueled by significant investments like their recent $5.74 billion valuation deal for Taicang IDC Campus phases, which will bolster their operational capacity significantly.

• Get an in-depth perspective on VNET Group's performance by reading our health report here.

• Evaluate VNET Group's historical performance by accessing our past performance report.

AbbVie (NYSE:ABBV)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AbbVie Inc. is a global research-based biopharmaceutical company focused on the development, production, and sale of medicines and therapies, with a market capitalization of approximately $360.27 billion.

Operations: The company generates revenue primarily from its Innovative Medicines and Therapies segment, which contributes $56.33 billion.

AbbVie, while not traditionally seen as a high-growth tech company, has demonstrated significant strides in its sector with an expected annual earnings growth of 25.3%, outpacing the US market average of 14.2%. Despite a revenue growth forecast at 5.9% per year, which lags behind the broader US market's 8.8%, the company's robust R&D investment and strategic financial maneuvers like recent fixed-income offerings totaling over $4 billion underscore its commitment to innovation and financial health. Recent approvals for new drugs and expansions in biotech partnerships highlight AbbVie’s focus on leveraging scientific advancements to secure long-term growth, positioning it as a resilient player in the evolving pharmaceutical landscape.

• Click to explore a detailed breakdown of our findings in AbbVie's health report.

• Explore historical data to track AbbVie's performance over time in our Past section.

Fair Isaac (NYSE:FICO)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Fair Isaac Corporation develops software with analytics and digital decisioning technologies to help businesses automate and enhance decisions globally, with a market cap of $42.30 billion.

Operations: Fair Isaac Corporation generates revenue primarily through its Scores and Software segments, with the Scores segment contributing $963.21 million and the Software segment adding $812.22 million. The company's operations span across various regions including the Americas, Europe, the Middle East, Africa, and Asia Pacific.

Fair Isaac, a leader in analytics software and scoring models, has shown robust financial performance with a 15.5% increase in quarterly revenue year-over-year, reaching $439.97 million. This growth is complemented by an impressive net income surge to $152.53 million from the previous year's $121.07 million, reflecting strong operational efficiency and market demand for its products like the FICO Score 10 T and innovative mortgage solutions. The company's commitment to research and development is evident from its strategic collaborations, such as with MCT for the U.S. secondary mortgage market, enhancing credit decision precision and promoting financial inclusivity globally.

• Click here and access our complete health analysis report to understand the dynamics of Fair Isaac.

• Review our historical performance report to gain insights into Fair Isaac's's past performance.

Summing It All Up

• Discover the full array of 225 US High Growth Tech and AI Stocks right here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com